We are proud to announce that PhenoPath is now a Quest Diagnostics Company.

PhenoPath, PLLC

Diagnoses you can count on®

PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.

PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:

Please see Biomarker Testing for Checkpoint Inhibitors for more information on PD-L1 22C3, PD-L1 28-8 and PD-L1 SP142.

Latest News

  • PhenoPath conference March 7th

    Please read the attached letter regarding the PhenoPath conference scheduled for March 7th, 2019

    Read More »

  • PhenoPath acquired by Quest Diagnostics

    Please read the attached letter for an important announcement regarding PhenoPath

    Read More »

  • Phenomena v21.1

    New FDA Approvals for PD-L1/PD-1 Targeted Therapies & Introducing the Combined Positive Score (CPS); New Assays MUC4 IHC and TFE3 (Xp11) FISH; Amyloid Analysis;...

    Read More »